Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saruparib
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Saruparib is an orally bioavailable, potent, and selective inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), with minimal effect on PARP2. It belongs to the class of PARP inhibitors and is being developed primarily for the treatment of various cancers characterized by homologous recombination repair deficiency, such as advanced solid tumors, metastatic castration-sensitive prostate cancer (mCSPC), and hormone receptor-positive/HER2-negative advanced breast cancer with BRCA1/BRCA2 or PALB2 mutations. By selectively inhibiting PARP1, saruparib impairs DNA repair in tumor cells, leading to synthetic lethality in cancers with defective homologous recombination repair mechanisms. This selectivity may offer a safer profile compared to nonselective PARPi and facilitate combination therapies with other DNA damage response inhibitors. Developed by: AstraZeneca
- Brand names
- saruparib
- Other names
- AZD5305AZD-5305AZD 5305saruparib
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on saruparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saruparib.